Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder.
Tumor lysis syndrome (TLS) may occur after the administration of rituximab for lymphoproliferative disorders. We describe the case of a heart transplant recipient who developed TLS after a single dose of rituximab for the treatment of posttransplant lymphoproliferative disorder. Because rituximab is being used more frequently, it is important for transplant physicians to be aware of this potential complication particularly after administering the first dose.
Francescone
S A
SA
Mount Sinai Medical Center, New York, New York 10029, USA.
Murphy
B
B
Fallon
J T
JT
Hammond
K
K
Pinney
S
S
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002311:Cardiomyopathy, Dilated / Q000601:surgery; D004554:Electric Countershock; D017809:Fatal Outcome; D016027:Heart Transplantation / Q000473:pathology*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D014184:Transplantation, Homologous / Q000473:pathology; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab